(BIM) Biomerieux - Ratings and Ratios
Chromogenic Media, Blood Culture, PCR Systems, Mass Spectrometry, AST
Dividends
| Dividend Yield | 0.80% |
| Yield on Cost 5y | 0.81% |
| Yield CAGR 5y | 9.76% |
| Payout Consistency | 96.0% |
| Payout Ratio | 28.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.2% |
| Value at Risk 5%th | 34.1% |
| Relative Tail Risk | -6.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | 0.90 |
| CAGR/Max DD | 0.40 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.404 |
| Beta | 0.046 |
| Beta Downside | 0.171 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.78% |
| Mean DD | 5.86% |
| Median DD | 4.80% |
Description: BIM Biomerieux January 03, 2026
bioMérieux S.A. (ticker BIM) designs, manufactures and sells in-vitro diagnostic (IVD) products for infectious disease detection across clinical and industrial markets worldwide. Its portfolio spans culture media (CHROMID), automated blood-culture systems (BACT/ALERT VIRTUO), multiplex PCR platforms (BIOFIRE, BIOFIRE SPOTFIRE), mass-spectrometry identification (VITEK MS), automated ID/AST solutions (VITEK 2, VITEK REVEAL, ETEST), whole-genome sequencing tools (EPISEQ CS), and a suite of software and consumables that support laboratory workflow and antimicrobial-resistance monitoring.
Key drivers for bioMérieux’s performance include: (1) Revenue growth of roughly 7 % YoY in 2023, propelled by rising demand for rapid-turnaround diagnostics and a 12 % increase in R&D spend to sustain pipeline innovation; (2) Operating margins expanding to ~18 % as the company leverages scale in its VITEK and BIOFIRE lines while maintaining a strong recurring-revenue stream from software and service contracts; (3) Sector-wide tailwinds such as the global IVD market’s projected CAGR of 5–6 % through 2030, driven by aging populations, heightened focus on antimicrobial-resistance surveillance, and the shift toward point-of-care testing in emerging regions (Africa, Middle East, APAC). These macro trends, combined with bioMérieux’s diversified geographic footprint, underpin its growth outlook.
If you want a data-rich, model-driven assessment of BIM’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can provide the quantitative depth you need.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (660.4m TTM) > 0 and > 6% of Revenue (6% = 408.5m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 8.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.68% (prev 19.94%; Δ -1.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 1.28b > Net Income 660.4m (YES >=105%, WARN >=100%) |
| Net Debt (125.9m) to EBITDA (1.53b) ratio: 0.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (118.9m) change vs 12m ago -0.04% (target <= -2.0% for YES) |
| Gross Margin 54.80% (prev 51.83%; Δ 2.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 128.2% (prev 106.6%; Δ 21.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 40.01 (EBITDA TTM 1.53b / Interest Expense TTM 25.9m) >= 6 (WARN >= 3) |
Altman Z'' 2.93
| (A) 0.24 = (Total Current Assets 2.28b - Total Current Liabilities 1.00b) / Total Assets 5.37b |
| (B) 0.03 = Retained Earnings (Balance) 161.0m / Total Assets 5.37b |
| (C) 0.19 = EBIT TTM 1.03b / Avg Total Assets 5.31b |
| (D) -0.03 = Book Value of Equity -48.6m / Total Liabilities 1.43b |
| Total Rating: 2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.05
| 1. Piotroski 9.50pt |
| 2. FCF Yield 4.56% |
| 3. FCF Margin 8.75% |
| 4. Debt/Equity 0.13 |
| 5. Debt/Ebitda 0.08 |
| 6. ROIC - WACC (= 12.42)% |
| 7. RoE 16.76% |
| 8. Rev. Trend 9.02% |
| 9. EPS Trend -9.53% |
What is the price of BIM shares?
Over the past week, the price has changed by +3.11%, over one month by +8.14%, over three months by -1.31% and over the past year by +7.10%.
Is BIM a buy, sell or hold?
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.2 | 10.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 116 | 2.7% |
BIM Fundamental Data Overview January 06, 2026
P/E Trailing = 34.6519
P/E Forward = 22.8311
P/S = 3.1366
P/B = 3.2864
P/EG = 1.8269
Beta = 0.652
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 506.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 13.05b EUR (12.93b + Debt 506.4m - CCE 380.5m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
EV/FCF = 21.91x (Enterprise Value 13.05b / FCF TTM 595.8m)
FCF Yield = 4.56% (FCF TTM 595.8m / Enterprise Value 13.05b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Gross Margin QoQ = 57.09% (prev 51.87%)
Tobins Q-Ratio = 2.43 (Enterprise Value 13.05b / Total Assets 5.37b)
Interest Expense / Debt = 1.48% (Interest Expense 7.50m / Debt 506.4m)
Taxrate = 24.67% (52.6m / 213.2m)
NOPAT = 779.2m (EBIT 1.03b * (1 - 24.67%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.13 (Debt 506.4m / totalStockholderEquity, last quarter 3.93b)
Debt / EBITDA = 0.08 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 0.21 (Net Debt 125.9m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.43% (Net Income 660.4m / Total Assets 5.37b)
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 24.91% (EBIT 1.03b / Capital Employed (Equity 3.94b + L.T.Debt 212.8m))
RoIC = 18.32% (NOPAT 779.2m / Invested Capital 4.25b)
WACC = 5.90% (E(12.93b)/V(13.43b) * Re(6.09%) + D(506.4m)/V(13.43b) * Rd(1.48%) * (1-Tc(0.25)))
Discount Rate = 6.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.02%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈413.0m ; Y1≈509.5m ; Y5≈867.7m
Fair Price DCF = 212.8 (EV 25.25b - Net Debt 125.9m = Equity 25.12b / Shares 118.1m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 7.57% | SUE: 1.17 | # QB: 1
EPS next Year (2026-12-31): EPS=4.97 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.4% | Growth Revenue=+6.4%